Published in Medical Letter on the CDC and FDA, June 15th, 2008
"Orally administered alogliptin demonstrated antidiabetic effects in preclinical studies in mice, rats, dogs and monkeys, as well as a good safety profile. Early clinical studies demonstrated that alogliptin can be safely co-administered with antidiabetic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA